In Japan, insurance coverage for breast implantation is limited to procedures using Allergen-manufactured products.
Researchers reviewed the clinical/pathologic aspects of HSTCL and summarized the latest molecular studies and potential novel therapeutic targets.
Delayed evaluation could decrease unnecessary invasive tests.
Among patients with cancer, tumor subtypes may influence varying susceptibility to SARS-CoV-2 and COVID-19 disease phenotypes.
Investigators measured ixazomib, dexamethasone, and rituximab combination treatment among patients with treatment-naive Waldenström macroglobulinemia.
A small study suggests that low-dose pembrolizumab or nivolumab may be effective and safe for the treatment of r/r classical Hodgkin lymphoma.
Researchers assessed diagnosis, risk-stratification, and management of 3 distinct subgroups of primary cutaneous lymphomas.
Using a grading system for skin flare reactions increases potential for continuing administration of mogamulizumab despite the occurrence of this adverse effect.
Novel immunotherapies and small molecule pathway inhibitors are transforming the standard of care for some of the most challenging lymphoma subtypes.
Neurotoxicity is a common AE associated with CAR-T administration, but there are limited data characterizing it among patients with LBCL who received axi-cel.
In this study, researchers determined that the quantity and quality of discussions regarding survivorship and late effects of treatment between AYA lymphoma survivors and their oncologists is improving, but survivorship information is still lacking.
While the rate of certain HIV-linked non-Hodgkin lymphomas has declined since the introduction of ART, the incidence of Burkitt lymphoma has remained steady.
Researchers studied clinical characteristics linked to overall survival and lymphoma-specific survival in patients with plasmablastic lymphoma.
Researchers evaluated data from younger patients with Waldenström macroglobulinemia to determine features that predict outcomes in this patient population.
The treatment reduced hospital stay but not neutropenia duration or infection rate.
The occurrence, severity, and need for treatment of cytokine release syndrome were key parameters in the assessment of CAR-T–related neurotoxicity risk.
All responders were found to have the same structural rearrangements.
Researchers at UT MD Anderson Cancer Center in Houston present tools that support patient adherence to acalabrutinb in the setting of MCL.
Identifying TP53 missense mutations through routine analysis is needed for patients with mantle cell lymphoma.
Study results suggest allogeneic SCT as standard consolidation therapy in pediatric patients with progression during frontline therapy or relapse of a CD3-positive ALCL.